Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immune checkpoint blockades (ICBs) represent a significant advancement in cancer treatment.
• Current ICBs targeting CTLA-4 and PD-1/PD-L1 do not benefit all patients.
• New immune checkpoint proteins (ICPs) are being investigated to overcome resistance.

Purpose of the Study:

• To review the discovery and therapeutic potential of second-wave ICP targets.
• To summarize the immunotherapy mechanisms of LAG-3, TIM-3, and TIGIT.
• To consolidate preclinical and clinical data for these emerging ICB targets.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of the discovery and biological mechanisms of LAG-3, TIM-3, and TIGIT.
• Evaluation of preclinical efficacy and clinical trial outcomes for ICBs targeting these proteins.

Main Results:

• Lymphocyte-activation gene-3 (LAG-3), T-cell immunoglobulin and mucin-domain-containing-3 (TIM-3), and T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) are key second-wave targets.
• These targets demonstrate promise in preclinical models and early clinical trials for solid tumors and leukemia.
• Understanding their mechanisms is crucial for optimizing combination strategies.

Conclusions:

• LAG-3, TIM-3, and TIGIT represent promising next-generation targets for cancer immunotherapy.
• Further research and clinical trials are essential to fully realize the potential of ICBs against these targets.
• These ICBs may expand treatment options for patients unresponsive to current therapies.